SOURCE-LINKED INTELLIGENCE

AI-powered embryonic phenotyping for accelerated drug discovery and toxicology

CORDIS · observation · Publication date unknown

AI-powered embryonic phenotyping for accelerated drug discovery and toxicology The EmbryoNet-AI project seeks to transform drug discovery and toxicology testing by integrating advanced deep learning technologies to automate phenotypic analysis of embryos and organoids. Traditional drug testing methods rely heavily on animal models, which are time-consuming, costly, and often ethically problematic. EmbryoNet-AI offers a faster, more accurate, and comprehensive solution for evaluating the effects of compounds on biological development, thus significantly enhancing the efficiency of early-stage drug screening. The core innovation is EmbryoNet-AI's ability to analyze complex biological data with precision, providing insights into drug mechanisms that are not only quicker but also more reliable than current methods. This will ultimately reduce the need for animal models in drug testing, addressing both ethical and logistical concerns. The EmbryoNet-AI platform is poised to fill a critical gap in the pharmaceutical and biotech industries, offering a scalable, non-invasive ap

Read original source ↗ Open in workspace

recordType

award

status

SIGNED

region

EU

value

150000

unit

EUR